News archive 2007
21 December 2007
Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
20 December 2007
Ablynx Extends Agreement with Wyeth
19 December 2007
Santaris Pharma signs global R&D alliance with GlaxoSmithKline in viral diseases
18 December 2007
Gilde Healthcare II invests EUR 7.5 million in Santaris Pharma
17 December 2007
Ablynx Reports Positive Phase 1 Results For It's Anti-Thrombotic Nanobody®, ALX-0081
17 December 2007
MammaPrint® Breast Cancer Test Shown to be Powerful Tool for Prognosis Prediction in Postmenopausal Breast Cancer Patients
14 December 2007
Agendia - Study Shows MammaPrint® Breast Cancer Test Provides Benefits to Patients from Personalized Treatment Regimen
13 December 2007
Agendia – MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
13 December 2007
Gilde Healthcare Partners co-leads EUR 17.6 million Series-A financing in Ascendis Pharma A/S
13 December 2007
Chroma Therapeutics announces positive phase I efficacy data for novel cancer therapy
12 December 2007
Agendia's MammaPrint®, the only FDA-cleared breast cancer prognosis test, is now widely available to U.S. patients
11 December 2007
FlowCardia, Inc. Launches Peripheral CROSSER(R) Catheter Portfolio in the US
10 December 2007
Ablynx Announces Extension Of Nanobody® Drug Discovery And Development Alliance
10 December 2007
Ablynx Raises An Additional €10.2 Million Via The Over-Allotment Option
7 December 2007
Ablynx Retains Important Commercial Claims in Key NANOBODY®-Patent Appeal
5 December 2007
FlowCardia, Inc. Appoints Chris Barys Senior VP, Sales
4 December 2007
Symphogen to Present Positive Preclinical Data on Sym003 Program for RSV Infection
8 November 2007
Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin®-based novel cancer therapy
6 November 2007
Ablynx raises €75 million in succesfull IPO
5 November 2007
Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
30 October 2007
Pieris and Pepscan to identify GPCR-specific Anticalins(R) using CLIPS[TM] protein mimicry technology
22 October 2007
Agendia BV appoints Clinical and Scientific Advisory Board
15 October 2007
Agendia acquires rights to the discovery of a major drug resistance mechanism in breast cancer potentially leading to a Herceptin® sensitivity test
10 October 2007
Ablynx announces intention to launch an Initial Public Offering (IPO) on Eurolist by Euronext Brussels
3 October 2007
Gilde Healthcare Partners Closes EUR 150 million European Healthcare Venture Fund
27 September 2007
Agendia joins the Personalized Medicine Coalition (PMC)
13 September 2007
Agendia BV appoints Mr. Hessel Lindenbergh as chairman of its Supervisory Board
7 September 2007
Ablynx and Boehringer Ingelheim Announce Major Global Strategic Alliance to Discover, Develop and Commercialise Novel Nanobody Therapeutics
6 September 2007
IDEA AG concludes Licence Agreement for its innovative targeted analgesic, Diractin®, with Alpharma
5 September 2007
Pieris Validates the Use of Anticalins® as Ophthalmologic Biotherapeutics
30 August 2007
FlowCardia, Inc. Raises $30 Million In Series C Financing
27 August 2007
Agendia BV raises €25 Million ($34M) and Receives Second FDA Clearance
6 August 2007
Ablynx Strengthens Management Team With The Appointment of Dr Josefin-Beate Holz as Chief Medical Officer
6 August 2007
BG Medicine Files US Registration Statement With SEC In Support of Euronext Amsterdam IPO
18 July 2007
Amsterdam Molecular Therapeutics raises additional € 5.67 million in IPO following partial exercise over-allotment option
10 July 2007
Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin®-Based Protein Product Candidate
2 July 2007
Ablynx Announces Interim Results Of First Nanobody® Phase 1 Study Of ALX-0081 (ANTI-VWF)
20 June 2007
Amsterdam Molecular Therapeutics announces pricing of Initial Public Offering (IPO) on Euronext Amsterdam
13 June 2007
Agendia appoints Dr. Jan Groen as Chief Operating Officer
13 June 2007
Chroma Progresses Novel Cancer Therapy CHR-2797 Into Phase II Solid Tumour Study; Presents Phase I Data at ASCO
23 May 2007
Conatus Pharmaceuticals Elects Harold E. Van Wart, Ph.D., to Its Board of Directors
23 May 2007
BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker
22 May 2007
Chroma Therapeutcis Strengthens Its Board through the Appointment of Klaus Veitinger as Non-Executive Director
22 May 2007
Amsterdam Molecular Therapeutics announces intention to launch an Initial Public Offering (IPO) on Euronext Amsterdam
16 May 2007
IDEA AG submits marketing application for its innovative targeted analgesic, Diractin®, to EMEA
9 May 2007
Conatus Pharmaceuticals Completes Second Closing of $27.5 Million Private Placement Financing
9 May 2007
Conatus Pharmaceuticals Completes Second Closing of $27.5 Million Private Placement Financing
7 May 2007
Symphogen Granted European Patent Covering Use of Polyclonal Antobodies for Allergy Indications
29 April 2007
Neuro3D Acquired By Evotec AG
29 April 2007
Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin(R) in Preclinical Studies
26 April 2007
Chroma Progresses Novel Cancer Therapy Into Phase II Clinical Development
21 February 2007
BG MEDICINE - Critical Path Liver Toxicity Biomarker Study to Commence with Participation from Seven Pharmaceutical Companies
6 February 2007
AGENDIA’s MammaPrint® breast cancer prognosis test cleared by U.S. Food and Drug Administration (FDA)
5 February 2007
AGENDIA announces a distribution agreement with Medvet Science, Australia
31 January 2007
Gilde Healthcare Partners invests in Symphogen A/S
30 January 2007
BG Medicine launches $30 million High-Risk Plaque Initiative together with leading healthcare companies Merck & Co, AstraZeneca, Royal Philips Electronics and Humana
8 January 2007
ABLYNX and BOEHRINGER INGELHEIM Sign $265 MILLION Research and Licensing Agreement to Develop new Alzheimer’s Treatments
3 January 2007
Gilde Healthcare Partners invests in Conatus Pharmaceuticals, Inc.
